Un­der pres­sure from ad­vo­cates, Vi­iV strikes a deal to make its long-act­ing HIV in­jectable more ac­ces­si­ble

A week af­ter ad­vo­cates called up­on Vi­iV Health­care to low­er the price of its long-act­ing HIV in­jectable Apre­tude, the com­pa­ny has struck a deal to make the drug more ac­ces­si­ble in low- and mid­dle-in­come coun­tries.

Vi­iV and the Med­i­cines Patent Pool (MPP) signed a vol­un­tary li­cens­ing agree­ment that will al­low gener­ic man­u­fac­tur­ers in 90 coun­tries to de­vel­op, man­u­fac­ture and sup­ply their own ver­sions of Apre­tude, “sub­ject to re­quired reg­u­la­to­ry ap­provals be­ing ob­tained,” the part­ners an­nounced on Thurs­day.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER